The restoration ofoxygenated blood to ischaemic myocardium -reperfusion-halts the process leading to infarction. Early reperfusion is the only way to prevent progression to myocardial necrosis and thus to limit the size of the infarct. It may also, however, injure the heart. This paradox has become clinically important with the advent of thrombolytic treatment and primary coronary angioplasty for acute myocardial infarction.
Several studies have shown that there are three main components of reperfusion injury: reperfusion arrhythmias, myocardial stunning, and lethal myocyte injury.
Sixty years ago Tennant and Wiggers recognised that the reintroduction of blood flow could cause arrhythmias.' In animal experiments arrhythmias may occur within seconds of the onset of reflow.' In humans reperfusion arrhythmias are commonly associated with intracoronary thrombolytic treatment3 and primary coronary angioplasty.4 I They may be less common after intravenous thrombolytic treatment,6 and in these circumstances it has been proposed that they pose no additional threat to life.7 The disparity may, however, be related to the rate of recanalisation. Yamazaki et al showed that in dogs sudden reperfusion was more likely to be associated with a high frequency of arrhythmias than was staged reperfusion.8 In a randomised clinical study comparing intravenous thrombolytic treatment with primary coronary angioplasty, ventricular fibrillation was significantly more common in the angioplasty group (6'7% v 200/).4 These studies provided angiographic proof of reperfusion-which was not available in several of the multicentre trials of thrombolysis.6 9 10 The duration of the preceding ischaemia is a second important determinant of vulnerability to arrhythmias after reperfusion. In another experiment on dogs Balke et al observed a peak of 67% in the frequency of ventricular fibrillation when reperfusion was achieved after [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] minutes of ischaemia, as opposed to 22% after 60 minutes." When thrombolytic treatment is given very early (and the intracoronary thrombus is fresh, less organised, and easier to lyse) reperfusion arrhythmias may be expected to be more prominent. A recent study by the European Myocardial Infarction Project Group randomised 5469 patients to thrombolytic treatment before admission or to later treatment in hospital. Although mortality did not differ in the two groups, prehospital ventricular fibrillation occurred significantly more often in patients treated out of hospital."2 Severe reperfusion arrhythmias may not be common, but the fact that they are life threatening makes them clinically relevant and not dismissible.
Myocardial stunning, which is a delay in functional improvement, is a second phenomenon that may occur after reperfusion. It seems to follow a time course similar to that observed in experiments on animals."3 A study by Schmidt et al on 264 patients found that the improvement of systolic performance in the reperfused region was only modest after three days but that considerably more recovery occurred between three days and six months.'4 Reviews by Bolli et al and Kloner have shown the clinical relevance of myocardial stunning, which may delay recovery from cardiogenic shock after reperfusion.'5 16 Myocardial stunning would seem to be reversible (given sufficient time), and it might therefore seem of little clinical importance. Moreover, studies on animals have shown that stunning may be corrected by inotropic agents.'7 The danger, however, is that in patients with acute left ventricular failure precipitated by myocardial infarction who have undergone reperfusion treatment, poor ventricular function due to stunning may be mistaken for permanent injury. Clinicians need to know that this contractile dysfunction may be reversible provided that inotropic (or mechanical) circulatory support is maintained-though we still do not know how much support is needed or for how long. A final complication is that large doses of inotropes not only increase myocardial oxygen demand but are also arrhythmogenic-two actions that may cause further haemodynamic decline.
The third phenomenon associated with reperfusion is lethal myocyte injury, but uncertainty continues about its clinical relevance-or indeed whether it occurs at all. One view is that reperfusion only accelerates the destruction of already irreversibly damaged cells.'8 Reperfusion has been shown toe induce contraction band necrosis, resulting in a weakened myocardium, which in turn may lead to cardiac rupture. Data from the second and third international studies of infarct survival (ISIS 2 and 3) and the study by the Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI) showed a small-but consistent-excess of deaths on the first day only.6910 This excess occurred in the first six hours and was largely due to cardiac rupture and cardiogenic shock, not bleeding or stroke. After the first day the benefits of thrombolytic treatment were similar regardless of age or time to presentation. The increased incidence of early cardiac rupture may be due not to reperfusion itself but to the modality of reperfusion. When 
